Gilead Sciences (GILD) Rises Yet Lags Behind Market: Some Facts Worth KnowingZacks Investment Research • 03/31/26
Can Gilead's Recent Acquisitions Strengthen Its Long-Term Growth Outlook?Zacks Investment Research • 03/27/26
Gilead Strengthens Inflammation Portfolio With Ouro Medicines DealZacks Investment Research • 03/24/26
Gilead Sciences to acquire Ouro Medicines, expanding autoimmune therapy portfolioProactive Investors • 03/24/26
Gilead to Buy Ouro Medicines for $2.2 Billion. ‘Immune Reset' Is Key to Future Gains.Barrons • 03/24/26
Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune DiseasesBusiness Wire • 03/23/26
Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending StockZacks Investment Research • 03/19/26
Gilead Sciences (GILD) Falls More Steeply Than Broader Market: What Investors Need to KnowZacks Investment Research • 03/18/26
Arcellx Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Arcellx, Inc. - ACLXBusiness Wire • 03/13/26
Will GILD's Move to Acquire ACLX Boost Its Cell Therapy Franchise?Zacks Investment Research • 03/13/26
The Zacks Analyst Blog Oracle, T-Mobile, Gilead, and C&F FinancialZacks Investment Research • 03/13/26
Gilead Sciences, Inc. (GILD) Presents at Barclays 28th Annual Global Healthcare Conference TranscriptSeeking Alpha • 03/11/26
Gilead Sciences, Inc. (GILD) Presents at Leerink Global Healthcare Conference 2026 TranscriptSeeking Alpha • 03/10/26
Gilead Gets a Buy, Amgen a Hold and ORIC a Vote of Confidence: Wall Street's Latest Biopharma Calls Explained24/7 Wall Street • 03/10/26